Introduction

Tuberculosis
(TB) is a communicable disease that has troubled physicians for thousands of years and has been a leading cause of death in Europe and the U.S.A. for centuries (1) . The introduction of effective antibiotics and public health strategies during the 20th century should have resulted in tuberculosis becoming a disease of the past. However, the number of cases of tuberculosis, in both developed countries and world-wide, is rising. The range of antibiotics available to treat Mycobacteviuln tuberculosis infections is long established (1, 2) and the discussion amongst physicians no longer surrounds which drugs to use, but the frequency and duration with which to use them. Originally treatment courses were for 2 years, but it is now accepted that a six month rifamycin containing regimen is effective (3). However, this still requires patients to take several tablets on a daily basis for a long time and for the greatest part of the course they have no symptoms. Non-compliance with medication for asymptomatic, chronic disease has been demonstrated to be in the region of 30&50% (4, 5, 6) . In tuberculosis this can result in both personal and public health risks and has been associated with the emergence of multi-drug resistant tuberculosis (1, 7, 8 (9) . However, when self administered, intermittent dosing did not promote compliance, but this is ensured by employing directly observed therapy (DOT). Directly observed intermittent therapy requires a responsible individual, who may be a healthcare professional, to give the medication to a patient and to ensure that all doses have been taken. This approach has been employed widely in the U.S.A., where it has emerged as the standard of care (10) .
The World Health Organisation (WHO) is convinced of the benefits to be gained by using DOT (11) although their view is not supported by all (12, 13) .
Both the British (14) and American (15,16) Thoracic Societies have issued guidelines on the dosing regimens that should be employed for DOT based largely on 'best practice' and they provide limited references to support the data.
Following a literature review of recent studies, evidence based dosing guidelines have been produced.
Literature review
The Iowa Drug Information Service and Medline databases were searched using the key words: tuberculosis, pulmonary tuberculosis, drug therapy and compliance. Five observational studies were identified which had clinical as opposed to sociological outcomes. One was discarded on the basis that insufficient detail was provided for comparative purposes (17) . The four studies considered suitable for the purposes of this review are summarized in Table 1 (21) reported on a retrospective study of Gran Canaria, who were followed for 2 yr (18) . Patients the treatment of 109 patients who had undergone DOT in were treated with a three-drug regimen, twice weekly for 6 the Kwazulu/Natal region of South Africa. A 95% success months. Eighty-seven patients (87%) completed therapy rate is stated. However the limitations to the follow-up having negative tests for acid-fast bacilli at the end of the process should be noted. The study population included treatment course. The WHO standards (1996) require an transient workers for whom objective follow-up was not 85% 'cure' rate for tuberculosis therapy regimens and possible. Data for these patients is based on third party therefore the results of this study are in the appropriate reports of good health. When the objective data is analysed range (20) . Relapse rate was 3.4% at 2 yr and two patients on an intention to treat basis, the cure rate is 75%. All stopped therapy due to adverse drug reactions.
patients completed therapy and the relapse rate was 4%. Neher et al. reported on the introduction of DOT for the treatment of tuberculosis in the Kathmandu valley (19) . Eight hundred and eighty-six patients were treated with a four-drug regimen, three times a week for a period of 9 months. Streptomycin was substituted for ethambutol if side-effects occurred. Patients were followed for 3 yr. Therapy failure and relapse rates were 1.6% and 1'3% respectively. An 85% cure rate was achieved.
Discussion
The dosage regimens for each study were based on varying mg kg-' doses and frequencies. If simplified by calculating the total weekly doses for a 60 kg adult, it becomes clear that all the studies used similar regimens. The Chinese Tuberculosis Control Collaboration reported on the first 3.5 yr of the DOT programme (20) . They treated 112 842 patients with a standard four-drug regimen on alternate days for 6 months. A fifth drug (ethambutol) was added if patients had previously received therapy. Over the first 3.5 yr 85.3% of patients were cured and a further 2.6% 'completed treatment'. In those patients who have been followed up for 2 yr a 3.2% relapse rate has been noted. Failure rates of 5.7% were noted. This study represents a huge success for DOT, as previously only 50% of patients with TB were cured and the disease was responsible for 300 000 deaths in China in 1990.
It is therefore suggested that doses for directly observed therapy for tuberculosis should be based on maximum weekly doses and divided into the appropriate frequency for the individual patient. Evidence based dosage guidelines for directly observed therapy, are shown in Table 2 The maximum dose of Rifampicin (600 mg dose-') produces plasma concentrations in excess of the mean inhibitory concentration for M. tuberculosis. Larger doses are therefore unnecessary and would be associated with an increased incidence of side-effects. The dosage frequency of streptomycin should be decreased in patients with renal failure; doses should be tailored to the individual patient. Baseline monitoring should be done before therapy is commenced prevention of the emergence of drug resistant strains. Directly observed therapy can increase the rate of course completion and appropriate doses of drugs and careful documentation should be used.
